139 related articles for article (PubMed ID: 38534935)
1. Ovarian Cancer in the Older Manitoban Population-Treatment Tolerance and Cancer-Related Outcomes: A Manitoba Ovarian Cancer Outcomes (MOCO) Group Study.
Roberts LF; Lambert P; Nachtigal MW; Altman AD; Dean E
Curr Oncol; 2024 Mar; 31(3):1348-1358. PubMed ID: 38534935
[TBL] [Abstract][Full Text] [Related]
2. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Gallardo-Rincon D; Blagden S; Brenton J; Perren TJ; Sundar S; Lord R; Dark G; Hall M; Banerjee S; Glasspool RM; Hanna CL; Williams S; Scatchard KM; Nam H; Essapen S; Parkinson C; McAvan L; Swart AM; Popoola B; Schiavone F; Badrock J; Fananapazir F; Cook AD; Parmar M; Kaplan R; Ledermann JA
Lancet Oncol; 2022 Jul; 23(7):919-930. PubMed ID: 35690073
[TBL] [Abstract][Full Text] [Related]
3. Examining the Effects of Time to Diagnosis, Income, Symptoms, and Incidental Detection on Overall Survival in Epithelial Ovarian Cancer: Manitoba Ovarian Cancer Outcomes (MOCO) Study Group.
Altman AD; Lambert P; Love AJ; Turner D; Lotocki R; Dean E; Popowich S; Nachtigal MW
Int J Gynecol Cancer; 2017 Oct; 27(8):1637-1644. PubMed ID: 28704327
[TBL] [Abstract][Full Text] [Related]
4. Response to Multi-Line Chemotherapy in Non-Serous Epithelial Ovarian Cancer.
Altman AD; Lambert P; Dean E; Robinson C; Nachtigal MW; Kean S
J Obstet Gynaecol Can; 2020 Oct; 42(10):1217-1222. PubMed ID: 32694071
[TBL] [Abstract][Full Text] [Related]
5. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
[TBL] [Abstract][Full Text] [Related]
6. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Hook J; Coyle C; Blagden S; Brenton JD; Naik R; Perren T; Sundar S; Cook AD; Gopalakrishnan GS; Gabra H; Lord R; Dark G; Earl HM; Hall M; Banerjee S; Glasspool RM; Jones R; Williams S; Swart AM; Stenning S; Parmar M; Kaplan R; Ledermann JA
Lancet; 2019 Dec; 394(10214):2084-2095. PubMed ID: 31791688
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
8. Perioperative Incidence of Venous Thromboembolism in Patients With Ovarian Cancer Using Four Different Data Collection Methods: A Manitoba Ovarian Cancer Outcomes (MOCO) Group Study.
Smith S; Lambert P; Nachtigal MW; Altman AD
J Obstet Gynaecol Can; 2022 May; 44(5):475-481. PubMed ID: 34718149
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
[TBL] [Abstract][Full Text] [Related]
10. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
[No Abstract] [Full Text] [Related]
11. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
12. Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
Kongsawatvorakul C; Charakorn C; Chittithaworn S; Lertkhachonsuk AA
J Obstet Gynaecol; 2022 Aug; 42(6):2331-2335. PubMed ID: 35470751
[TBL] [Abstract][Full Text] [Related]
13. Rate of Appendiceal Metastasis with Non-Serous Epithelial Ovarian Cancer in Manitoba.
Altman AD; Lefas G; Power L; Lambert P; Lotocki R; Dean E; Nachtigal MW
J Obstet Gynaecol Can; 2018 Feb; 40(2):180-185. PubMed ID: 28826644
[TBL] [Abstract][Full Text] [Related]
14. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Vergote I; Scambia G; O'Malley DM; Van Calster B; Park SY; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM; Covens A; Marth C; Raza Mirza M; Kroep JR; Ma H; Pickett CA; Monk BJ;
Lancet Oncol; 2019 Jun; 20(6):862-876. PubMed ID: 31076365
[TBL] [Abstract][Full Text] [Related]
15. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
duPont NC; Enserro D; Brady MF; Moxley K; Walker JL; Cosgrove C; Bixel K; Tewari KS; Thaker P; Wahner Hendrickson AE; Rubin S; Fujiwara K; Casey AC; Soper J; Burger RA; Monk BJ
Gynecol Oncol; 2022 Feb; 164(2):398-405. PubMed ID: 34857397
[TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review.
Parikh R; Kurosky SK; Udall M; Chang J; Cappelleri JC; Doherty JP; Kaye JA
Int J Gynecol Cancer; 2018 May; 28(4):738-748. PubMed ID: 29538247
[TBL] [Abstract][Full Text] [Related]
18. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
[TBL] [Abstract][Full Text] [Related]
19. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
20. No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population.
Salvador S; Scott S; Francis JA; Agrawal A; Giede C
J Obstet Gynaecol Can; 2017 Jun; 39(6):480-493. PubMed ID: 28527613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]